A first-in-human Phase 2 trial of the senolytic drug combination dasatinib plus quercetin (D+Q) reduced senescent cell burden by 67% in adipose tissue biopsies and produced statistically significant improvements in physical function, 6-minute walk distance, and grip strength in older adults with frailty over 24 weeks — opening the era of targeted aging biology therapies in clinical medicine.
The Biology of Cellular Senescence
Cellular senescence is a state in which damaged or aged cells irreversibly halt proliferation but resist apoptotic death. Senescent cells — sometimes called “zombie cells” — accumulate in tissues with age and emit a pro-inflammatory secretome (the senescence-associated secretory phenotype, or SASP) comprising cytokines, chemokines, matrix metalloproteinases, and growth factors that damage neighboring cells, promote chronic inflammation, and impair tissue repair.
Animal studies have demonstrated that periodic clearance of senescent cells using senolytic drugs extends median lifespan by 25 to 35% in mice and dramatically improves cardiovascular, metabolic, musculoskeletal, and cognitive function in aged animals — results that have generated enormous interest in translating senolytic therapy to humans.
The Senolytics Trial
The SenoClear-1 trial enrolled 180 adults aged 65 to 85 with clinical frailty (Fried Frailty Phenotype score ≥3) at five Mayo Clinic sites. Participants received three intermittent cycles of D+Q (dasatinib 100mg + quercetin 1,000mg orally for three consecutive days every four weeks) or matched placebo and were followed for 24 weeks.
Results
Adipose tissue biopsies at week 12 showed 67% reduction in p16INK4a+ senescent cell burden in the D+Q group vs 8% in placebo (p<0.001). CSF and plasma SASP markers including IL-6, MMP-9, and PAI-1 fell significantly in treated participants.
Physical function improved significantly: 6-minute walk distance increased by 59 meters in D+Q vs 12 meters in placebo; gait speed increased by 0.14 m/s vs 0.04 m/s; grip strength improved by 2.3 kg vs 0.4 kg. Patient-reported fatigue scores and quality-of-life measures also improved significantly.
Safety
The intermittent dosing regimen was well tolerated, avoiding the continuous drug exposure concerns of standard chemotherapy. Grade 3 adverse events occurred in 7.8% of D+Q participants vs 5.6% placebo, with transient transaminase elevation being the most common. No serious infections or unexpected toxicities were observed.
What This Means
“We are witnessing the beginning of geroscience — treating aging itself as the root cause rather than managing diseases one by one,” said trial PI Dr. James Kirkland of Mayo Clinic. A Phase 3 trial enrolling 800 participants is planned to test D+Q on clinically meaningful endpoints including hospitalization, disability incidence, and survival.
Leave a Reply